Allergen-specific immunoglobulin E against Alternaria alternata (sIgE (Alternaria))

Allergen-specific immunoglobulin E (IgE) antibodies against Alternaria alternata are specialized proteins produced by the immune system that recognize and bind to allergens from the Alternaria mold, particularly the major allergen Alt a 1 [1]. These antibodies play a central role in the pathogenesis of mold-induced allergic diseases by sensitizing mast cells and basophils through their interaction with the high-affinity IgE receptor, FcεRI [2]. When an individual is re-exposed to Alternaria spores, the allergens cross-link the IgE molecules on the cell surface, leading to the rapid release of inflammatory mediators such as histamine, cytokines, and leukotrienes [1, 2]. This physiological response manifests clinically as allergic rhinitis and is a significant risk factor for the development of severe, persistent asthma [2]. Therapeutic intervention often involves the use of anti-IgE monoclonal antibodies, such as Omalizumab, which sequester circulating IgE and prevent it from binding to its receptors on effector cells [3]. Furthermore, allergen-specific immunotherapy (AIT) is employed to modify the underlying immune response, often resulting in a decrease in specific IgE levels and an increase in protective IgG4 antibodies [4].

Other names

Alternaria-specific IgEAnti-Alternaria IgEIgE to Alternaria alternatasIgE Alternaria

Binding to the Cε3 domain of circulating IgE, thereby preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils [3].